Pharma BD Deal Intelligence
A $10.5B licensing deal that gave Pfizer access to Innovent's 12-program oncology pipeline of ADCs and multispecific antibodies for just $650M upfront. Innovent carries programs through Phase 1 before Pfizer takes over global development, making this a bet on China-originated discovery rather than a near-term revenue driver.
Pfizer, Innovent Biologics Forge $10.5 Billion Oncology Collaboration to Advance Next-Generation Cancer Therapies. The value of licensing agreements involving…
China's Innovent Biologics signs drug deal with Pfizer worth up to $10.5bn. The Chinese biotech and U.S. pharmaceutical giant signed a licensing agreement for…
Deepening Ties: Why China is Becoming Big Pharma's Most Essential R&D Partner. Total deal value for China biotech out-licensing climbed to $135.7 billion in…
Source summaries from our enrichment pipeline; follow links for originals.
All 14 sources with sentiment breakdown →
On May 28, 2026, Pfizer and China's Innovent Biologics entered a global strategic oncology collaboration worth up to $10.5 billion to develop a portfolio of 12 early-stage cancer programs spanning antibody-drug conjugates (ADCs) and multispecific antibodies — eight Innovent-originated programs and four Pfizer-proposed discovery programs. Innovent receives $650 million upfront and is eligible for up to $9.85 billion in development, regulatory and commercial milestones plus up to double-digit royalties. Innovent leads development through Phase 1, after which Pfizer assumes global development; four programs will be co-developed and co-commercialized with shared U.S./Europe profits. It is one of the largest China-originated oncology partnerships to date.
Broad oncology collaboration spanning a 12-program portfolio of antibody-drug conjugates with novel payloads and multi-specific antibodies across solid-tumor targets (specific antigens undisclosed). The deal exemplifies Big Pharma's accelerating in-licensing of China-originated early-stage oncology innovation.
Eight Innovent-originated programs (developed by Innovent through Phase 1) plus four Pfizer-proposed de novo discovery programs. Pfizer obtains ex-China rights with profit-sharing on co-developed/co-commercialized programs in the US and Europe; up to double-digit royalties.
Pfizer and Innovent entered a global strategic oncology collaboration worth up to $10.5B ($650M upfront + up to $9.85B milestones) to develop 12 early-stage cancer programs (8 Innovent-originated ADC/multispecific programs + 4 Pfizer-proposed de novo programs), with up to double-digit royalties and US/EU profit-sharing on co-developed programs.
Deal remains pending. Trade press reports the parties expect completion in Q3 2026, subject to required regulatory approvals (the primary release does not name a precise date). Separately, the bipartisan Biotech Investment National Security Act (BINSA), introduced in the House, would subject US-China biotech licensing/IP deals to Treasury and Defense Department national-security review -- a new political/regulatory risk to the closing path and to the broader China-sourced-innovation thesis.
Transaction between Pfizer and Innovent Biologics is pending completion. Assessment will be updated upon deal close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Pfizer Inc. / Innovent Biologics, Inc. (this deal) | 2026 | $10.5B | 71 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Pfizer Inc. / FoldRx Pharmaceuticals | 2010 | — | 99 |
| Pfizer Inc. / Medivation Inc. | 2016 | $14.0B | 86 |
| Pfizer Inc. / Wyeth | 2009 | $68.0B | 86 |
| Pfizer Inc. / Warner-Lambert Company | 2000 | $90.0B | 83 |
| Pfizer Inc. / Arvinas, Inc. | 2021 | $2.4B | 77 |
← Browse all deals · How we score deals
More: 2026 deals · Pfizer Inc. deals · Oncology deals